The industry might consider coordinating an effort to prevent advisory committees from using outcomes as tools to present one-sided versions of price negotiations.
If this does signal a new way of communicating, the industry has tools to deploy
July 9, 2024 Latest NewsBioPharmaCommentLatest Video
New Stories
-
How many people will die because of this institutional indifference?
October 22, 2024 - - Latest News -
Patients slam PBAC's failure to streamline cancer medicines access
October 22, 2024 - - Latest News -
Moderna releases Winter report card highlighting the impact of respiratory illnesses
October 22, 2024 - - Latest News -
Alcon supports future optometrists through new educational grant
October 21, 2024 - - Latest News -
US FDA grants rare paediatric designation to PYC's drug development program
October 21, 2024 - - Australian Biotech -
Only those not confronting a life-ending diagnosis can view hope as intangible and false
October 21, 2024 - - Latest News -
Disappointment in response to status quo recommendation on new process
October 21, 2024 - - Latest News